09-0015 USAF C-32A on final Oshkosh, WI-Wittman Airport-should be on ground right about now
09-0017 USAF C-32A went to Adams County Legion Field located adjascent to Castle Rock Lake and upstream from Wisconsin Dells. Froze at about 3050 ft about 30 minutes ago
SNTRY26 USAF E-3C AWACS still trackin'
Schrodinger, Inc. sold by co-founder: $31.02m-August 17
Schrödinger Announces Closing of Public Offering
Schrödinger, Inc. (the "Company") (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the closing of its underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $66.00 per share. The offering consisted of 5,250,000 shares sold by the Company, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, and 500,000 shares sold by a selling stockholder. The gross proceeds to the Company in the offering were $346.5 million. The Company did not receive any of the proceeds from the sale of the shares by the selling stockholder. Morgan Stanley, BofA Securities, Jefferies and BMO Capital Markets acted as joint book-running managers for the offering.
https://finance.yahoo.com/news/schr-dinger-announces-closing-public-203000838.html
Schrodinger, Inc. provides computational software solutions for drug discovery to the bio-pharmaceutical industry. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company's software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of pre-clinical and clinical drug programs, internally and through collaborations. Its platform integrates solutions for predictive modeling, data analytics and collaboration. Its wholly-owned programs include SDGR1, SDGR2, SDGR3, SDGR4 and SDGR5. SDGR1 and SDGR2 drug discovery programs are focused on targets that mediate de-oxyribonucleic acid (DNA) repair, cell cycle regulation, replication stress responses, and apoptosis, or programmed cell death. SDGR3, SDGR4 and SDGR5 drug discovery programs are focused on genetically-defined cancers. Number of employees : 394 people.
https://www.marketscreener.com/SCHRODINGER-INC-102588712/company/
The company is headquartered in New York City. Schrödinger's partners include larger pharmaceutical companies, including Takeda and Sanofi. Nimbus Therapeutics, co-founded by Schrödinger, uses Schrödinger's drug screening and design platform for drug discovery. In 2016, Nimbus Therapeutics sold an Acetyl-CoA carboxylase (ACC) inhibitor designed by Schrödinger to Gilead in a deal worth up to $1.2 billion. As of spring 2019 the ACC inhibitor was moving through late-stage clinical trials in NASH. Richard A. Friesner is an American theoretical chemist and William P. Schweitzer Professor of Chemistry at Columbia University. He was elected to the American Academy of Arts and Sciences in 2008, and the National Academy of Sciences in 2016. Richard Friesner co-founded Schrödinger in 1990.
https://en.wikipedia.org/wiki/Richard_A._Friesner
https://www.finviz.com/insidertrading.ashx?oc=1798426&tc=7&b=2